<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870503</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/201/19</org_study_id>
    <nct_id>NCT03870503</nct_id>
  </id_info>
  <brief_title>Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage</brief_title>
  <official_title>Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Post-partum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the effectiveness and safety of carbetocin vs.&#xD;
      oxytocin plus sublingual misoprostol in the management of atonic postpartum hemorrhage&#xD;
      (PPH)after vaginal delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first cause of hemorrhage at the time of delivery is uterine atony; therefore, there is&#xD;
      general agreement that active management of the third stage of labor is recommended.&#xD;
&#xD;
      Oxytocin is the most widely used uterotonic agent but has a half-life of only 4-10 min, that&#xD;
      is why it is better administered as a continuous intravenous infusion to achieve sustained&#xD;
      uterotonic activity. Carbetocin is a synthetic long-acting oxytocin agonistic analog with&#xD;
      prolonged half-life prolonging its pharmacological effects. Its prolonged uterine activity&#xD;
      may theoretically offer advantages over oxytocin in the management of the third stage of&#xD;
      labor. The side-effect profile of carbetocin was not found to be different from that of&#xD;
      Oxytocin but may prove to be advantageous when compared to Syntometrine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be a prospective double-blind randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study will be a prospective double-blind randomized study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of blood loss</measure>
    <time_frame>6 hours post delivery</time_frame>
    <description>calculation of the amount of blood loss by weighing the swabs and using pictorial charts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients develop blood loss more than 1000 ml</measure>
    <time_frame>24 hours post delivery</time_frame>
    <description>Calculation of the number of patients develop blood loss more than 1000 ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patient need blood transfusion</measure>
    <time_frame>24 hours post delivery</time_frame>
    <description>Calculation of number of patient need blood transfusion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be received oxytocin 20 IU by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin plus misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be received Carbetocin 100 mic gm IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>The patient will be received oxytocin 20 IU by intravenous infusion</description>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_label>oxytocin plus misoprostol</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin plus misoprostol</intervention_name>
    <description>The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol</description>
    <arm_group_label>oxytocin plus misoprostol</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>The patient received Carbetocin 100 mic gm</description>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All participants had PPH defined as vaginal bleeding&gt;500 ml after vaginal delivery and&#xD;
             uterine atony confirmed by abdominal palpation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  gestational age&lt;37 weeks,&#xD;
&#xD;
          -  genital tract trauma,&#xD;
&#xD;
          -  coagulation defect,&#xD;
&#xD;
          -  women with hypertension, preeclampsia, cardiac, renal or liver diseases, epilepsy&#xD;
&#xD;
          -  known hypersensitivity to carbetocin or oxytocin.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All participants had PPH defined as vaginal bleeding&gt;500 ml after vaginal delivery and uterine atony confirmed by abdominal palpation</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f allam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2019</study_first_submitted>
  <study_first_submitted_qc>March 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Postpartum Hemorrhage</keyword>
  <keyword>vaginal delivery</keyword>
  <keyword>carbetocin</keyword>
  <keyword>misoprostol</keyword>
  <keyword>oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

